Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Effect of Symbicort on Sleep Quality in Patients With Emphysema
Effect of Symbicort on Sleep Quality in Patients With Emphysema
Status: Enrolling
Updated:  5/18/2012
Temple Lung Center
mi
from
Philadelphia, PA
Effect of Symbicort on Sleep Quality in Patients With Emphysema
Effect of Symbicort on Sleep Quality in Patients With Emphysema
Status: Enrolling
Updated: 5/18/2012
Temple Lung Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Pilot Study to Improve Patient-Doctor Communication
A Pilot Study to Improve Patient-Doctor Communication
Status: Enrolling
Updated:  5/23/2012
Walter Reed National Medical Military Center (WRNMMC)
mi
from
Bethesda, MD
A Pilot Study to Improve Patient-Doctor Communication
A Pilot Study to Improve Patient-Doctor Communication
Status: Enrolling
Updated: 5/23/2012
Walter Reed National Medical Military Center (WRNMMC)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Nurse Managed Sequential Strength Training and Bicycle Training in Chronic Obstructive Pulmonary Disease (COPD)
Nurse Managed Sequential Resistance Then Aerobic Training in COPD
Status: Enrolling
Updated:  5/29/2012
University of Illinois at Chicago
mi
from
Chicago, IL
Nurse Managed Sequential Strength Training and Bicycle Training in Chronic Obstructive Pulmonary Disease (COPD)
Nurse Managed Sequential Resistance Then Aerobic Training in COPD
Status: Enrolling
Updated: 5/29/2012
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease
A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease.
Status: Enrolling
Updated:  6/18/2012
VA WNY Healthcare System
mi
from
Buffalo, NY
A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease
A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease.
Status: Enrolling
Updated: 6/18/2012
VA WNY Healthcare System
mi
from
Buffalo, NY
Click here to add this to my saved trials
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Status: Enrolling
Updated:  7/5/2012
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Status: Enrolling
Updated: 7/5/2012
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Status: Enrolling
Updated:  7/5/2012
University of North Carolina Hospitals - Sanford Specialty Clinics
mi
from
Sanford, NC
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Status: Enrolling
Updated: 7/5/2012
University of North Carolina Hospitals - Sanford Specialty Clinics
mi
from
Sanford, NC
Click here to add this to my saved trials
Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent)
Status: Enrolling
Updated:  7/18/2012
UCLA
mi
from
Los Angeles, CA
Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent)
Status: Enrolling
Updated: 7/18/2012
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
Efficacy of Inhaling Bronchodilator Medications in Patients With Chronic Obstructive Pulmonary Disease Who Have a Low Peak Inspiratory Flow Rate
Status: Enrolling
Updated:  9/28/2012
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
Efficacy of Inhaling Bronchodilator Medications in Patients With Chronic Obstructive Pulmonary Disease Who Have a Low Peak Inspiratory Flow Rate
Status: Enrolling
Updated: 9/28/2012
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Promoting Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) Through New Technology and Health Coaching
Next Generation Technology for Chronic Care Self Management
Status: Enrolling
Updated:  10/24/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Promoting Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) Through New Technology and Health Coaching
Next Generation Technology for Chronic Care Self Management
Status: Enrolling
Updated: 10/24/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Novel Unidirectional Face Mask During Noninvasive Positive Pressure Ventilation (NPPV) in Chronic Obstructive Pulmonary Disease (COPD) Patients
Use of a Novel Unidirectional Face Mask During Noninvasive Positive Pressure Ventilation (NPPV) in Chronic Obstructive Pulmonary Disease (COPD) Patients
Status: Enrolling
Updated:  11/5/2012
Massachusetts General Hospital
mi
from
Boston, MA
A Novel Unidirectional Face Mask During Noninvasive Positive Pressure Ventilation (NPPV) in Chronic Obstructive Pulmonary Disease (COPD) Patients
Use of a Novel Unidirectional Face Mask During Noninvasive Positive Pressure Ventilation (NPPV) in Chronic Obstructive Pulmonary Disease (COPD) Patients
Status: Enrolling
Updated: 11/5/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Stepping up to Health - for Veterans With Chronic Obstructive Pulmonary Disease (COPD)
Effectiveness of an Automated Walking Program Targeting Veterans With COPD
Status: Enrolling
Updated:  11/14/2012
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Stepping up to Health - for Veterans With Chronic Obstructive Pulmonary Disease (COPD)
Effectiveness of an Automated Walking Program Targeting Veterans With COPD
Status: Enrolling
Updated: 11/14/2012
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/14/2012
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/14/2012
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/14/2012
1268.17.01031 Boehringer Ingelheim Investigational Site
mi
from
Easley, SC
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/14/2012
1268.17.01031 Boehringer Ingelheim Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/14/2012
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/14/2012
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  11/14/2012
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (Low Dose, High Dose), Tiotropium (Low Dose, High Dose) and Olodaterol (One Dose Only) (Oral Inhalation, Delivered by the RESPIMAT Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 11/14/2012
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
e-Counseling for COPD
Psychosocial-Behavioral Therapy for Patients With Advanced COPD and Depression
Status: Enrolling
Updated:  11/29/2012
Univ of Washington
mi
from
Seattle, WA
e-Counseling for COPD
Psychosocial-Behavioral Therapy for Patients With Advanced COPD and Depression
Status: Enrolling
Updated: 11/29/2012
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy of Losartan in Preventing Progression of COPD
Efficacy of Losartan in Preventing Progression of COPD
Status: Enrolling
Updated:  1/10/2013
Johns Hopkins Asthma and Allergy Center
mi
from
Baltimore, MD
Efficacy of Losartan in Preventing Progression of COPD
Efficacy of Losartan in Preventing Progression of COPD
Status: Enrolling
Updated: 1/10/2013
Johns Hopkins Asthma and Allergy Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Improving Clinician Communication Skills (ICCS)
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Status: Enrolling
Updated:  1/21/2013
Medical University of South Carolina
mi
from
Charleston, SC
Improving Clinician Communication Skills (ICCS)
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Status: Enrolling
Updated: 1/21/2013
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Improving Clinician Communication Skills (ICCS)
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Status: Enrolling
Updated:  1/21/2013
University of Washington; Harborview Medical Center
mi
from
Seattle, WA
Improving Clinician Communication Skills (ICCS)
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Status: Enrolling
Updated: 1/21/2013
University of Washington; Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Improving Clinician Communication Skills (ICCS)
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Status: Enrolling
Updated:  1/21/2013
University of Washington; UW Medical Center
mi
from
Seattle, WA
Improving Clinician Communication Skills (ICCS)
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Status: Enrolling
Updated: 1/21/2013
University of Washington; UW Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Improving Clinician Communication Skills (ICCS)
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Status: Enrolling
Updated:  1/21/2013
Veteran's Affairs Puget Sound HCS
mi
from
Seattle, WA
Improving Clinician Communication Skills (ICCS)
Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses
Status: Enrolling
Updated: 1/21/2013
Veteran's Affairs Puget Sound HCS
mi
from
Seattle, WA
Click here to add this to my saved trials
Outlook: An Intervention to Improve Quality of Life in Serious Illness
Outlook: An Intervention to Improve Quality of Life in Serious Illness
Status: Enrolling
Updated:  1/22/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Outlook: An Intervention to Improve Quality of Life in Serious Illness
Outlook: An Intervention to Improve Quality of Life in Serious Illness
Status: Enrolling
Updated: 1/22/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects
A Randomized, Double-blind, Single Dose, Four Way Cross-over Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol Following Single Inhaled Doses of Umeclidinium/Vilanterol Blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in Healthy Subjects
Status: Enrolling
Updated:  1/31/2013
GSK Investigational Site
mi
from
Bethesda, MD
A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects
A Randomized, Double-blind, Single Dose, Four Way Cross-over Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol Following Single Inhaled Doses of Umeclidinium/Vilanterol Blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in Healthy Subjects
Status: Enrolling
Updated: 1/31/2013
GSK Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients
Evaluation of Effect of Breathe Ventilation System on Work of Breathing in COPD Patients
Status: Enrolling
Updated:  2/4/2013
Tufts Medical Center
mi
from
Boston, MA
Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients
Evaluation of Effect of Breathe Ventilation System on Work of Breathing in COPD Patients
Status: Enrolling
Updated: 2/4/2013
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01198 Boehringer Ingelheim Investigational Site
mi
from
Florence, AL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01198 Boehringer Ingelheim Investigational Site
mi
from
Florence, AL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1199.34.10078 Boehringer Ingelheim Investigational Site
mi
from
Scottsdale, AZ
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1199.34.10078 Boehringer Ingelheim Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1245.25.10035 Boehringer Ingelheim Investigational Site
mi
from
Anaheim, CA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1245.25.10035 Boehringer Ingelheim Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01038 Boehringer Ingelheim Investigational Site
mi
from
Encinitas, CA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01038 Boehringer Ingelheim Investigational Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1199.14.1164 Boehringer Ingelheim Investigational Site
mi
from
Fullerton, CA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1199.14.1164 Boehringer Ingelheim Investigational Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01171 Boehringer Ingelheim Investigational Site
mi
from
Lincoln, CA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01171 Boehringer Ingelheim Investigational Site
mi
from
Lincoln, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.440.1002 Boehringer Ingelheim Investigational Site
mi
from
Torrance, CA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.440.1002 Boehringer Ingelheim Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1237.5.01015 Boehringer Ingelheim Investigational Site
mi
from
Boulder, CO
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1237.5.01015 Boehringer Ingelheim Investigational Site
mi
from
Boulder, CO
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01040 Boehringer Ingelheim Investigational Site
mi
from
Stamford, CT
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01040 Boehringer Ingelheim Investigational Site
mi
from
Stamford, CT
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1268.17.01045 Boehringer Ingelheim Investigational Site
mi
from
Deland, FL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1268.17.01045 Boehringer Ingelheim Investigational Site
mi
from
Deland, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
Boehringer Ingelheim Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01135 Boehringer Ingelheim Investigational Site
mi
from
Ormond Beach, FL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01135 Boehringer Ingelheim Investigational Site
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01195 Boehringer Ingelheim Investigational Site
mi
from
Panama City, FL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01195 Boehringer Ingelheim Investigational Site
mi
from
Panama City, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01240 Boehringer Ingelheim Investigational Site
mi
from
Pensacola, FL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01240 Boehringer Ingelheim Investigational Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1264.3.01019 Boehringer Ingelheim Investigational Site
mi
from
Port Orange, FL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1264.3.01019 Boehringer Ingelheim Investigational Site
mi
from
Port Orange, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01231 Boehringer Ingelheim Investigational Site
mi
from
Tamarac, FL
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01231 Boehringer Ingelheim Investigational Site
mi
from
Tamarac, FL
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01130 Boehringer Ingelheim Investigational Site
mi
from
Atlanta, GA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01130 Boehringer Ingelheim Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01047 Boehringer Ingelheim Investigational Site
mi
from
Austell, GA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01047 Boehringer Ingelheim Investigational Site
mi
from
Austell, GA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1275.1.01111 Boehringer Ingelheim Investigational Site
mi
from
Duluth, GA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1275.1.01111 Boehringer Ingelheim Investigational Site
mi
from
Duluth, GA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
1199.14.1178 Boehringer Ingelheim Investigational Site
mi
from
Lawrenceville, GA
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
1199.14.1178 Boehringer Ingelheim Investigational Site
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated:  3/20/2013
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Status: Enrolling
Updated: 3/20/2013
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials